The mazda pharma Guide 5th August to 11th August 2013 | Page 64
?AR M AC ? PH
“Roche delivered strong operating results in the first half of 2013, driven by our existing portfolio, recently launched cancer medicines Perjeta and Kadcyla, as well as continued growth in the clinical laboratory business.” Schwan added, “We will continue to focus on innovation with 68 new molecular entities in our Pharma pipeline and 55 key Diagnostics platforms and tests in development.” Demand for Roche's three major cancer treatments MabThera/Rituxan,
EU
TIC
AL N
EW
S
Strides' standalone net sales increased by 10.3 per cent to Rs.312.17 crore from Rs.283.07 crore in the similar period of last year. Its EBDITA moved up by 6.5 per cent to Rs.88.48 crore from
year's sales growth, at constant exchange rates. Core EPS is targeted to grow ahead of sales. In 2013, Roche expects to further increase its dividend.
STRIDES ARCOLAB STANDALONE NET SALES DECLINE BY 7.3%, EBDITA BY 24% IN Q2
Mumbai : Strides Arcolab has registered lower standalone net sales and EBDITA during the second quarter ended June 2013. Its standalone net sales declined by 7.3 per cent to Rs.150.83 crore from Rs.162.65 crore in the corresponding period of last year. Its EBDITA also moved down by 24.1 per cent to Rs.39.69 crore from Rs.52.32 crore. Its other operating income declined by over 58 per cent to Rs.15.60 crore
Rs.83.05 crore. The company provided lower amount of Rs.11.59 crore for forex loss as against Rs.77.05 in the same period of last year. Due to lower forex loss, it achieved net profit of Rs.33.73 crore as against a net loss of Rs.48.06 crore in the last period. Profit before exceptional items increased by 46 per cent to Rs.42.03 crore from Rs.28.78 crore as its interest cost declined significantly to Rs.28.40 crore from Rs.45.40 crore in the previous half year. Under the restructuring programme, Strides Specialties (Holdings) Ltd, Mauritius has been transferred from Agila Specialities Pvt Ltd, India to Strides Pharmaceuticals Ltd, Cyprus during the second quarter of 2013. Inbiopro Solutions Pvt Ltd, India has been transferred from Agila Specialities Pvt Ltd, India to the company. Further, Agila Marketing e Distribicao de Productos Hospitalaries Limiteda, has been transferred from Strides Pharmaceuticals Ltd to Agila Specialties Americas, Cyprus. The Singapore based Agila specialities Global Pte Ltd has acquired balance 49 per cent stake in Agila Australasia Pty Ltd from JNZ Tango Pty Ltd, Australia, making Agila Australasia Pty Ltd a wholly owned subsidiary of the group. The company incorporated two new subsidiaries namely, Strides Pharma Inc., USA and Strides Actives Pvt Ltd, India. Similarly, Strides Pharma Ltd, Cyprus has divested its stake in Scentia Pharmaceuticals Pty Ltd, Australia to Amneal Pharma Australia Pty Ltd, Australia.
Avastin and Herceptin remained strong in the first half of 2013. Sales of Avastin were particularly good, rising 12 per cent, due to its increased use in ovarian cancer in Europe and colorectal cancer in both Europe and the United States. The HER2 breast cancer franchise (+11 per cent) is showing good growth following the recent launches of Perjeta and Kadcyla. Roche's Professional Diagnostics business area recorded a six per cent increase in
sales as a result of the division's broad offering of from Rs.37.19 crore. The company has opted tests, software and services. This was partly compensated by a decline in Diabetes Care of five per cent, reflecting a difficult market environment and continued pricing pressure. Roche further strengthened the outlook for its haematology franchise with encouraging data on obinutuzumab (GA101) and the Bcl-2 inhibitor RG7601, which Roche is developing with AbbVie. Study outcomes were presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) and at the 18th Annual Meeting of the European Haematology Association (EHA) in June. As previously announced, Roche decided to stop all trials involving aleglitazar after a regular safety review of the AleCardio phase III trial investigating aleglitazar in type 2 diabetes detected safety signals and lack of efficacy. Based on the strong operational performance in the first half of the year, Roche confirms its full-year outlook. Group sales in out of reporting consolidated results as the company sold Agila business to Mylan Inc. during February 2013. With lower provision for foreign exchange loss of Rs.12.43 crore as against Rs.45.92 crore, it reported a net profit of Rs.2.16 crore as compared to net loss of Rs.19.90 crore in the similar quarter of last year. The company is setting up biotech facility at Bio-Xcell ecosystem, Malaysia and the ground breaking scheduled in fo ??????????Q????????????????????????????????????????????????%??????????????????UL????????????????????????????????Q??????????????????????????????????????????????????????????????-???????????????????? ????